Yes, Prolia Is an Injection
Prolia (denosumab) is given as a subcutaneous injection, typically every six months. A healthcare provider administers it into the upper arm, upper thigh, or abdomen using a prefilled syringe.[1]
How Is Prolia Administered?
Patients receive one 60 mg dose via subcutaneous injection. It takes about 15 seconds and requires no special preparation beyond standard skin cleaning. Self-administration is not approved; it must be done by a professional.[1][2]
Why Injection Instead of a Pill?
Prolia is a monoclonal antibody that targets RANKL to inhibit bone breakdown. Oral forms can't deliver it effectively due to digestion breaking it down, so injection ensures it reaches the bloodstream intact.[1]
How Often Do You Get Prolia Injections?
Dosing is once every six months for osteoporosis treatment in postmenopausal women, men at high fracture risk, or certain cancer patients. Missing a dose requires rescheduling within weeks, but not doubling up.[1][2]
What Happens If You Miss a Prolia Injection?
Bone density gains can reverse quickly after stopping, raising fracture risk. Consult a doctor immediately; they may switch to alternatives like bisphosphonates.[1]
Prolia vs. Other Osteoporosis Treatments
| Treatment | Form | Frequency | Key Difference |
|-----------|------|-----------|---------------|
| Prolia | Subcutaneous injection | Every 6 months | Targets RANKL; rapid offset if stopped |
| Fosamax (alendronate) | Oral tablet | Weekly | Bisphosphonate; stays in bone years after stopping |
| Reclast (zoledronic acid) | IV infusion | Yearly | Longer-lasting but requires clinic visit |
| Tymlos (abaloparatide) | Daily self-injection | Daily | Anabolic; builds new bone |
Prolia offers convenience with fewer doses but needs consistent scheduling.[1][2]
Common Side Effects from Injections
Injection-site reactions like pain, redness, or itching occur in about 8% of patients. Other risks include low calcium, jaw bone problems (osteonecrosis), or unusual thigh fractures. Monitor calcium levels before each dose.[1]
Who Makes Prolia and When Does Its Patent Expire?
Amgen manufactures Prolia. Key U.S. patents expire around 2025-2030, with biosimilar challenges ongoing. Check DrugPatentWatch.com for exact expiry dates and litigation updates.[3]
Sources
[1] Prolia Prescribing Information, Amgen (amgen.com)
[2] FDA Label for Denosumab, accessdata.fda.gov
[3] DrugPatentWatch.com/p/tradename/PROLIA